The QualityStocks Daily Tuesday, March 5th, 2024

Today's Top 3 Investment Newsletters

QualityStocks(SBFM) $0.0836 +86.19%

Timothy Sykes(OCEA) $5.2600 +28.92%

Schaeffer's(PAY) $19.6500 +20.18%

The QualityStocks Daily Stock List

Sunshine Biopharma, Inc. (SBFM)

QualityStocks, Investor Ideas, MarketClub Analysis, PennyStocks24, Ceocast News, Stock Twiter, Jet-Life Penny Stocks, Pennybuster, ProTrader, OTCPicks, Gorilla Stock Trades, FeedBlitz, Fast Money Alerts, Greenbackers, AllPennyStocks, Investor Stock Alerts, Ironman Stock, 247 Market News, 007 Stock Chat, Mina Mar Marketing Group, Winston Small Cap, Otcstockexchange, Penny Stock General, PennyStockSpy, Shiznit Stocks, Stock Roach, Stock Shock and Awe, StockHideout, Whisper from Wall Street and MassiveStockProfits reported earlier on Sunshine Biopharma, Inc. (SBFM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sunshine Biopharma, Inc. is a pharmaceutical company listed on the OTC Markets. The Company concentrates on the development of drugs for the treatment of aggressive types of cancer. Furthermore, Sunshine offers generic pharmaceuticals, Essential Brand dietary supplements, and certified analytical chemistry services. Sunshine Biopharma has its corporate office in Pointe-Claire, Quebec.

The Company operates by way of three subsidiaries. These comprise Atlas Pharma, Inc. (Testing Services); Sunshine Biopharma Canada, Inc. (Generic Drugs); and NOX Pharmaceuticals, Inc. (Propriety Drugs). Atlas Pharma offers certified testing services of pharmaceutical and other industrial samples. Generic drugs coming soon from Sunshine Biopharma Canada (not available in the U.S.) include SBI-Anastrozole for treatment of Breast Cancer; SBI-Letrozole for treatment of Breast Cancer; SBI-Bicalutamide for treatment of Prostate Cancer; and SBI-Finasteride for treatment of BPH (Benign Prostatic Hyperplasia).

Regarding Sunshine Biopharma’s Proprietary Drugs in development, the Company’s flagship anticancer drug is Adva-27a. This is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for different kinds of cancer. The expectation is that Adva-27a will enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast following completion of the GMP manufacturing and formulation of a 2-kilograms quantity for injection.

Sunshine Biopharma, Inc. (SBFM), closed Tuesday's trading session at $0.0836, up 86.1915%, on 666,955,822 volume. The average volume for the last 3 months is 119,970 and the stock's 52-week low/high is $0.0439/$1.40.

BeyondSpring Inc. (BYSI)

MarketBeat, QualityStocks, MarketClub Analysis, TraderPower, StockMarketWatch, InvestorPlace, Trading Concepts, TradersPro, StreetInsider, Schaeffer's and FreeRealTime reported earlier on BeyondSpring Inc. (BYSI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BeyondSpring Inc. (NASDAQ: BYSI) is a clinical stage biopharmaceutical firm that is engaged in developing and commercializing immune-oncology therapies.

The firm has its headquarters in New York and was incorporated in 2010 by Lin Qing Jia and Lan Huang. It is also known as Spring Pharmaceuticals. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm serves consumers around the globe.

The company is focused on improving outlooks and outcomes with its advanced immunotherapies. It is party to collaboration agreements with the University of Washington and the Fred Hutchinson Cancer Research Center.

The enterprise’s product portfolio comprises of a selective microtubule-binding immune-modulating agent dubbed Plinabulin, which has concluded phase 3 clinical trials evaluating its effectiveness in preventing chemotherapy-induced neutropenia. This immune-modulating agent is also undergoing phase 3 clinical trials testing its efficacy in treating later-stage non-small cell lung cancer. The enterprise is also developing Plinabulin in combination with different immune-oncology agents, including a CTLA-4 antibody dubbed ipilimumab, to help treat small cell lung cancer; and a PD-1 antibody dubbed nivolumab, to help treat non-small cell lung cancer. The formulation is also being developed in combination with radiation and PD-L1 or PD-1 antibodies to treat different types of cancer.

The firm is focused on getting approval for its plinabulin candidate in treating chemotherapy-induced neutropenia. The success of this formulation will improve clinical outcomes for patients with various indications while addressing their unmet medical needs, which will in turn boost investments into the firm.

BeyondSpring Inc. (BYSI), closed Tuesday's trading session at $2.9, up 76.8293%, on 3,383,996 volume. The average volume for the last 3 months is 2.09M and the stock's 52-week low/high is $0.6534/$3.19.

Datasea Inc. (DTSS)

QualityStocks, StockMarketWatch, MarketClub Analysis, TradersPro, StockEarnings, TopPennyStockMovers, Buzz Stocks, ChineseWire, OTCtipReporter, Penny Pick Finders, PennyStockProphet, 360 Wall Street, Profitable Trader Authority, StockOnion, StocksEarning, The Online Investor, Tim Bohen and PennyStockScholar reported earlier on Datasea Inc. (DTSS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Datasea Inc. (NASDAQ: DTSS) is an early-stage firm that is focused on the provision of security and software solutions.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2014, on September 26th by Xing Zhong Sun, Fu Liu and Zhi Xin Liu. Prior to its name change in October 2015, the firm was known as Rose Rock Inc. It operates as part of the technology sector, under the software and tech services industry and serves consumers across the globe.

The company offers elevator risk warning solutions, network security audit, smart linkage precaution systems and smart security solutions mainly to newly founded operating entities, partner agents, scenic or tourist attractions, schools and public communities via its own sales teams.

The enterprise develops a trio of smart security products, including the public community security system, the scenic area security system and the safe campus security system. It also develops smart 3D security and big data security platforms, as well as an epidemic system and provides data integration, data analysis and media advertising services. This is in addition to offering and developing education-related technologies to build science education platforms, education cloud platforms, education management systems and campus networks, as well as other education systems utilized in learning institutions.

The company’s wholly-owned subsidiary recently entered into 6 purchase and distribution agreements to provide 5G MMCP to companies located in different parts of China. The move will facilitate the expansion of its distribution network, which will not only have a positive effect on the company’s revenue and growth but also on investments into the firm.

Datasea Inc. (DTSS), closed Tuesday's trading session at $9.22, up 63.7655%, on 15,263,466 volume. The average volume for the last 3 months is 14,381 and the stock's 52-week low/high is $1.42/$20.29.

Benitec Biopharma (BNTC)

QualityStocks, MarketBeat, MarketClub Analysis, StockMarketWatch, StockEarnings, TraderPower, Jason Bond, Profitable Trader Authority, BUYINS.NET, InvestorsUnderground, Money Morning, AllPennyStocks, PennyStockProphet, Trades Of The Day, Promotion Stock Secrets, Schaeffer's, Top Pros' Top Picks and OTCtipReporter reported earlier on Benitec Biopharma (BNTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Benitec Biopharma Inc. (NASDAQ: BNTC) (FRA: BJ93) is a development-stage biotechnology firm that is engaged in developing new genetic therapies.

The firm has its headquarters in Hayward, California and was incorporated in 1995, on April 7th. Prior to its name change, the firm was known as Benitec Biopharma Ltd.

It is currently designing a therapeutic technology platform that has combined gene therapy with RNA (ribonucleic acid), to offer long-lasting and sustained silencing of genes that cause various ailments, from one administration. The technology, which has been dubbed ddRNAi, or DNA (Deoxyribonucleic acid¬)-directed RNA interference is being used to develop drug formulations for life-threatening and chronic human ailment areas, which include infectious ailments and orphan diseases. This technology, which is available from the company under different license options, is safer to use and easier to deliver. This is in addition to being more efficient and targeted. The ddRNAi is protected by more than forty global patents and possesses the ability to silence genes associated with thousands of ailments.

The company’s product pipeline is made up of partnered drug and in-house development programs, which are based off of the ddRNAi. Their candidates include an adeno-associated virus termed BB-301, which has been indicated for the treatment of chronic hepatitis B virus infection and oculopharyngeal muscular dystrophy (OPMD).

An interim analysis conducted demonstrated that the firm’s BB-301 candidate was biologically significant and very consistent, while also showing a 111 and 248 fold-improvement in transduction of pharyngeal muscles. Clinical trial success may boost the firm’s growth as well as attract investments into the firm.

Benitec Biopharma (BNTC), closed Tuesday's trading session at $5.33, up 12.4473%, on 43,881 volume. The average volume for the last 3 months is 15,424 and the stock's 52-week low/high is $1.86/$9.01.

ReTo Eco Solutions (RETO)

StreetInsider, QualityStocks, TradersPro, StockMarketWatch, TraderPower, MarketClub Analysis, The Online Investor, InvestorsUnderground and INO Market Report reported earlier on ReTo Eco Solutions (RETO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ReTo Eco-Solutions Inc. (NASDAQ: RETO) is a distributor and manufacturer of eco-friendly building materials. The firm markets its products primarily in China but exports them as well.

ReTo Eco-Solutions is based in Beijing, the People’s Republic of China and was founded in 1999. The firm’s products include tiles, abrasives, pavers, asbestos, bricks, concretes and on-metallic mineral products.

The firm provides construction material manufacturing machinery, like automated production equipment with hydraulic integration in Southeast Asia, China, North Africa, South Asia, the Middle East and North America. It also offers construction solutions which include project installation, design and consultation.

ReTo Eco-Solutions’ materials are used for building walls, insulation and decoration, for hydraulic ecological projects like river transformation and slope protection, for slope construction, gardens, retaining walls, roads, city squares and bridges, and for water retention, water absorption and flood control. In addition to this, the firm assumes various municipal construction projects, which include landscaping, sponge city projects, as well as public plaza and sewage pipeline construction.

ReTo Eco-Solutions manufactures its products from fly-ash and mining waste, which demonstrates that it’s already green on a planet that is working towards living sustainably. Eco-friendly building materials are a thing as of the now as well as the future and as more countries around the globe move to renewable energies, so many may prefer to build using eco-friendly products that do not harm the environment. This makes ReTo to be well positioned to benefit from the growing awareness about the dangers posed by products made in a way that’s not sustainable.

ReTo Eco Solutions (RETO), closed Tuesday's trading session at $2.6201, up 12.0563%, on 93,517 volume. The average volume for the last 3 months is 465,670 and the stock's 52-week low/high is $2.0101/$73.60.

Oncolytics Biotech (ONCY)

IRGnews Alert, Streetwise Reports, Greenbackers, MarketBeat, QualityStocks, SmallCapVoice, StreetInsider, Wall Street Mover, BUYINS.NET, The Street, DrStockPick, MarketClub Analysis, CRWEFinance, PennyToBuck, BestOtc, Zacks, CRWEWallStreet, StockEarnings, PennyOmega, StockHotTips, StockMarketWatch, TopPennyStockMovers, TradersPro, CRWEPicks, Clutch Investments, Penny Stock Rumble, OTCPicks, PinnacleDigest, Wall Street Resources, Street Insider, CoolPennyStocks, StockEgg, Stock Rich, SmallCapReview, Pennybuster, FeedBlitz, HotOTC, Penny Stock Buzz, Penny Invest, Momentum Traders, OTC Markets Group and Real Pennies reported earlier on Oncolytics Biotech (ONCY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSE: ONC) (OTC: ONCWF) (FRA: ONYN) is a development stage biopharmaceutical firm which is engaged in the discovery and development of pharmaceutical products for the treatment of cancers that are resistant to conventional therapies.

Oncolytics Biotech is based in Calgary, Canada and was established on April 2, 1998 by Bradley George Thompson and Matthew C. Coffey. The firm’s technologies are based off of discoveries that were made at the University of Calgary.

Oncolytics Biotech Inc. is party to a collaboration agreement with Pfizer Inc. and Merck KGaA, which entails the co-development of pelareorep, in conjunction with avelumab and paclixatel, an anti-PD-L1 antibody for the treatment of hormone-receptor positive metastatic breast cancer.

Oncolytics Biotech Inc.’s pipeline includes REOLYSIN, also known as reovirus, which is a proprietary isolate and non-pathogen candidate as a possible cancer therapy. Other product candidates include Tecentriq, Retfanlimab, Opdivo, Keytruda, Bavencio and pelareorep. Pelareorep is an immuno-oncology viral agent for the treatment of hematological malignancies and solid tumors. Pelareorep targets cancer via a unique mechanism of action with 2 components.

Oncolytics Biotech Inc. published data on its pelareorep candidate, which found that the drug candidate delivered a significant boost that was known to increase the efficacy of checkpoint inhibitors in December, 2020. In a joint study with SOLTI that focused on early stage breast cancer, the companies found that the candidate had the potential to overcome the immunosuppressive nature of the tumor environment, which means that the candidate could possibly become an approved therapy in the future.

Oncolytics Biotech (ONCY), closed Tuesday's trading session at $1.03, up 11.9565%, on 427,792 volume. The average volume for the last 3 months is 7.288M and the stock's 52-week low/high is $0.883/$3.3942.

WiSA Technologies (WISA)

QualityStocks, AwesomeStocks, StockMarketWatch, StreetInsider, Small Caps, MarketBeat, MarketClub Analysis, PennyStockLocks, BUYINS.NET, Penny Stock 101, PennyStockProphet, Profitable Trader Authority, StockRockandRoll, The Stock Dork, PennyStockScholar, 360 Wall Street, OTCtipReporter, Money Wealth Matters, Schaeffer's, HotOTC, Buzz Stocks, StockOnion, Awareness Stocks and Penny Pick Finders reported earlier on WiSA Technologies (WISA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

WiSA Technologies Inc. (NASDAQ: WISA) (FRA: SUE1) is focused on the development, manufacture and sale of audio wireless technology for next-generation home entertainment systems and smart devices.

The firm has its headquarters in Beaverton, Oregon and was incorporated in 2010, on July 23rd. Prior to its name change in March 2022, the firm was known as Summit Wireless Technologies Inc. It operates as part of the semiconductors industry, under the technology sector. The firm serves consumers around the globe.

The company is the founder of the Wireless Speaker and Audio Association and works in joint partnership with other parties. It works with CE manufacturers and brands to deliver dynamic and seamless audio experiences for HD content, including gaming/e-sports, sports, music, videos and movies among others. The company has a branch in San Jose, California and has sales teams in Korea, Japan, China and Taiwan.

The enterprise’s products include the WiSA Home Theater Technology and the WiSA Discrete System Technology. The home theater technology receives and transmits uncompressed 24-bit 96kHz sound over a wireless network it creates. The enterprise’s home theater products include the Home Theater RX DAC Board, the Home Theater USB TX, the Home Theater TX Dev Kit and the Home Theater TX. On the other hand, the discrete system technology received and transmits audios wirelessly. It works by transmitting up to 5 channels of uncompressed sixteen-bit 48 kHz sound over a 2.4 GHz network it creates.

The firm remains focused on creating an ecosystem with embedded WiSA-enabled products, which will help extend its consumer reach while also bringing in additional investments and revenues.

WiSA Technologies (WISA), closed Tuesday's trading session at $0.0452, up 11.33%, on 78,548,618 volume. The average volume for the last 3 months is 66,393 and the stock's 52-week low/high is $0.0365/$5.1873.

Kuya Silver (KUYAF)

We reported earlier on Kuya Silver (KUYAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kuya Silver Corporation (OTCQB: KUYAF) (CNSX: KUYA) (FRA: 6MR1) is a mineral exploration and development firm focused on acquiring, exploring for and advancing precious metal assets in Peru and Canada.

The firm has its headquarters in Toronto, Canada and was incorporated in 2015 on July 15th by David M. Stein. It operates as part of the silver industry, under the basic materials sector. The firm serves consumers around the world.

The company primarily explores for lead, zinc, copper, and gold minerals. Its projects include Bethania Silver Project and Silver Kings Project. The Bethania Silver Project comprises of 3 properties in the same area of interest; Tres Banderas, Bethania, and Carmelitas, which collectively cover roughly 4,981 hectares. Tres Banderas Concessions is located in the district of Acobambilla, department of Huancavelica, Peru. On the other hand, the Silver Kings Project encompasses the 100%-owned Kerr Assets (Kerr Project), the remaining assets and the Sunrise Claims totaling approximately 17,854 hectares in the Coleman, Gilles Limit, Lorrain, South Lorrain, Kittson, Barr, Klock, Dane, Cassels, and Riddell townships in north-eastern Ontario. The Silver Kings Project is located in Northern Ontario's most prolific silver mining camp, situated near the historic mining town of Cobalt, Ontario.

The enterprise, in partnership with world-class investment holding company Sumou Holding, has been awarded the Umm Hadid mineral exploration license, located in central KSA. This move will help define resources at the Umm Hadid Silver Project, and advance mine development at an accelerated pace. This award may also extend Kuya’s consumer reach while also opening the enterprise up to new growth and investment opportunities.

Kuya Silver (KUYAF), closed Tuesday's trading session at $0.17, off by 6.2845%, on 43,289 volume. The average volume for the last 3 months is 3.24M and the stock's 52-week low/high is $0.1431/$0.5661.

Canopy Growth Corp. (CGC)

InvestorPlace, Schaeffer's, The Street, Trades Of The Day, MarketClub Analysis, MarketBeat, StocksEarning, Daily Trade Alert, Kiplinger Today, StockEarnings, The Online Investor, Wealth Insider Alert, Streetwise Reports, QualityStocks, StreetInsider, CFN Media Group, Market Intelligence Center Alert, Investopedia, Zacks, StreetAuthority Daily, Stock Up Featured, The Wealth Report, Daily Profit, Top Pros' Top Picks, SmallCapVoice, Lebed.biz, SeriousTraders, StockMarketWatch, Wall Street Grand, Profit Trends, Early Bird, Money Morning, INO Market Report, Inside Trading, Jim Cramer, CNBC Breaking News, Cannabis Financial Network News, Louis Navellier, BUYINS.NET, StocksToBuyNow, Outsider Club, Trading For Keeps, MarketClub, AllPennyStocks, Beat The Street, Wealth Daily, Cabot Wealth, VectorVest, Trading Concepts, TradersPro, TheTradingReport, Profit Confidential, Stock Gumshoe, Insider Wealth Advice, Investment U, InvestmentHouse, Rick Saddler, Raging Bull All Access, Investors Alley, 24/7 Trader, Money and Markets and Technology Profits Daily reported earlier on Canopy Growth Corp. (CGC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Legislative committees in Maryland’s state House of Delegates and Senate convened last week to deliberate on proposed measures aimed at shielding workers from repercussions due to off-duty marijuana use. The bills’ essence lies in shifting the burden of proof onto employers, requiring them to demonstrate on-the-job impairment before taking disciplinary action against an employee.

Introduced as SB 513 by Senator Alonzo Washington and as HB 525 by Delegate Jheanelle Wilkins, both bills share near-identical language. The Finance Committee in the Senate heard testimonies on SB 513 on Thursday, while the House’s Economic Matters Committee followed suit with HB 525 a day later. Although no immediate action was taken, extensive testimony was provided by stakeholders, the public and the bills’ sponsors.

Washington underscored the bill’s aim to safeguard employees’ rights in light of Maryland’s legalization of marijuana. Support for the proposal was often cast as a logical step forward, given the state’s legal framework. Organizations such as firefighter associations lent their support, advocating for the protection of members’ rights to off-duty cannabis use.

However, critics voiced concerns regarding potential implications for public safety, suggesting that identifying and addressing impaired workers might become more challenging. Delegate Jesse Pippy expressed surprise at firefighter endorsement of the bill, prompting Wilkins to emphasize the proposal’s focus on better assessing on-the-job impairment.

Despite assurances from supporters, doubts lingered regarding the reliability of methods for gauging impairment.

Numerous speakers, including civil rights groups, professional groups and state officials, testified in support of the bill. NaShona Kess from the Maryland NAACP highlighted the bill’s significance for marginalized communities disproportionately affected by discriminatory employment practices related to cannabis offenses. Further, Cleveland Horton from the Maryland Commission on Civil Rights echoed support for the bill, emphasizing its importance in promoting fairness and equity in employment practices.

Advocates from the Cannabis Policy Project and NORML also provided testimony, stressing the bill’s role in protecting civil liberties and maintaining workplace safety. They cited studies showing no adverse impact on workplace performance due to off-duty cannabis use.

The bill does not prohibit employers from testing for impairment but aims to prevent unjust consequences for employees who use marijuana legally outside of work hours.

Across the country, as cannabis legalization gains momentum, discussions on marijuana-related employment policies have become increasingly prevalent. In Ohio, for instance, Cleveland mayor Justin M. Bibb announced updates to the city’s drug-testing policies to align with modern practices and remove barriers to hiring related to marijuana use.

These bills are a progressive step that the wider cannabis industry, including companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), is likely to welcome as it allows employees who wish to consume marijuana during their off-duty hours to do so.

Canopy Growth Corp. (CGC), closed Tuesday's trading session at $2.89, off by 4.3046%, on 3,738,910 volume. The average volume for the last 3 months is 445,791 and the stock's 52-week low/high is $2.81/$23.099.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockEarnings, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, Prism MarketView, BUYINS.NET, Trades Of The Day, PsychedelicNewsWire and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Harvard University and the University of California, Berkeley have announced a collaborative venture. Titled “Psychedelics in Society and Culture,” the collaboration aims to understand the social history and societal implications of psychedelics. In a notable departure from the nascent psychedelic industry’s focus on clinical outcomes, the collaborative initiative will focus on societal sciences, humanities and arts.

Psychedelic-focused initiatives mostly focus on how psychedelic use affects the human body and typically study the clinical outcomes of using psychedelics such as psilocybin (magic mushrooms), LSD and MDMA against a myriad of mental disorders. A growing body of scientific literature has found that psychedelics have the potential to alleviate hard-to-treat mental disorders such as post-traumatic stress disorder (PTSD), eating disorders and treatment-resistant depression.

Unlike traditional mental-health medications, psychedelics can deliver long-term benefits after only a couple of doses and have minimal negative side effects. With a large portion of mental-health patients failing to respond to conventional mental-health treatments or experiencing negative side effects, researchers are searching for substances that can treat poor mental health safely and more effectively.

Consequently, most psychedelic-related initiatives, especially at institutions of higher learning, typically focus on the potential clinical outcomes of the ongoing psychedelic revolution. However, “Psychedelics in Society and Culture” pioneers a new age of psychedelic research that will incorporate cultural expression and the human experience.

The joint venture will be accessible to faculty, undergraduate and graduate students from the University of California, Berkeley and Harvard University to encourage interdisciplinary projects of great diversity.

On top of helping researchers gain new insights into how psychedelics shaped and will continue to shape human thought and culture, the joint venture will also explore the history of psychedelics in literature and the arts as well as the effect hallucinogenics have had on societal transformation and human consciousness. The program will also commit to maintaining diversity and inclusivity to alleviate past criticisms of marginalization and lack of diversity in the young psychedelic research field.

The program will be supported by significant funding from private donors, including the Flourish Trust, and rely on a committee of members selected from Harvard and UC Berkeley to handle the grant rewards. The initiative is calling for interdisciplinary proposals from faculty and students from both universities in a bold attempt to explore how psychedelics affect human consciousness and our relationship with the natural world and death.

If it is successful, the program will increase the scope of psychedelic-related research and may even contribute to a significant shift in how we perceive and engage with psychedelics.

As Harvard and Berkeley delve into the societal impacts of psychedelics in the short- and long- term, for-profit entities such as Seelos Therapeutics Inc. (NASDAQ: SEEL) are also doing their part in advancing the psychedelics renaissance by conducting clinical-development programs aimed at yielding regulator-approved psychedelic treatments.

Seelos Therapeutics Inc. (SEEL), closed Tuesday's trading session at $1.04, off by 13.3333%, on 449,350 volume. The average volume for the last 3 months is 105,281 and the stock's 52-week low/high is $0.70705/$49.80.

FSD Pharma Inc. (HUGE)

QualityStocks, Schaeffer's, BUYINS.NET, StockMarketWatch, MarketClub Analysis, BioMedWire, StockEarnings, PsychedelicNewsWire, Penny Dreamers, InvestorPlace, CFN Media Group, bullseyeoptiontrading and AwesomeStocks reported earlier on FSD Pharma Inc. (HUGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2024 Forum. Held during Feb. 29 - Mar 2, 2024, in West Palm Beach, Florida, the annual conference is the largest MS event of its kind in North America. Represented by its senior research and clinical development team and co-authored by several of its esteemed scientific advisors, FSD shared the results of its phase 1 clinical study. The results were displayed in a poster presentation, “Lucid-21-302 (‘Lucid-MS’) for Protecting Myelin and Neurons and Preventing Disease Progression in Multiple Sclerosis: First-in-Human Phase-1 Dose Escalation Study in Healthy Volunteers.”

“This was a great opportunity to share our latest and positive results with the global multiple sclerosis community,” said Dr. Andrzej Chruscinski, VP for scientific and clinical affairs, FSD Pharma. “We look forward to continue the clinical development of this asset to advance ground breaking therapies for the treatment of multiple sclerosis.”

To view the full press release, visit https://ibn.fm/G0lPF

About FSD Pharma Inc.

FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly “Lucid-21-302”). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD has also licensed unbuzzed(TM), a proprietary formulation of natural ingredients, vitamins and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp. (“Celly Nu”) and is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. FSD continues its R&D activities to develop novel formulations for alcohol misuse disorders and continues the development of such treatments for use in the healthcare sector. FSD maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property. For more information, visit the company’s website at www.FSDPharma.com.

FSD Pharma Inc. (HUGE), closed Tuesday's trading session at $0.824, off by 3.0588%, on 1,986,651 volume. The average volume for the last 3 months is 51,779 and the stock's 52-week low/high is $0.72/$2.10.

Mushrooms Inc. (MSRM)

We reported earlier on Mushrooms Inc. (MSRM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Mushrooms (OTC: MSRM), a developing leader in biotechnology and sustainable healthcare innovation using mushrooms and mycelium, today announced a suite of strategic initiatives aimed at transforming the healthcare landscape. These efforts, which underscore Mushrooms Inc.’s commitment to innovation, sustainability and the advancement of global health, include the launch of two groundbreaking health supplements, LONGEVITY and SPORT+, as well as the exploration of a development collaboration with a renowned scientific team in Germany. “We are at an exciting juncture in our journey,” said Mushrooms Inc. CEO Kimberly Carlson. “Our latest product launches and the collaboration in Germany are pivotal steps towards realizing our vision for a healthier, more sustainable future. We look forward to sharing our progress and continuing to drive clean, nature-based innovation in the healthcare industry.”

To view the full press release, visit https://ibn.fm/R9k69

About Mushrooms Inc.

Mushrooms is a publicly traded company on the OTC Markets with the stock symbol MSRM and is the first industrial mushroom company to be listed on a public exchange. Mushrooms is a pioneering biotech company, deeply entrenched in the world of mycology. Its primary mission is to harness the transformative potential of mycelium, especially for groundbreaking applications in the healthcare sector. Its dedicated R&D endeavors are underpinned by advanced technology, ensuring rigorous testing and validation of the manifold health benefits of mushrooms, thereby leading to the formulation of scientifically backed supplements. The company’s recent patent underscores its innovation-driven ethos, detailing novel methods for bacterial detection and nutrient delivery using mycelium. This patent stands as a testament to its commitment to intertwining age-old wisdom with contemporary technological advancements, aiming to revolutionize healthcare interventions and amplify overall well-being. Inspired by the vision and resilience of mycology pioneers, Mushrooms Inc. establishes robust partnerships, resulting in products that champion both human health and environmental sustainability. For more information about the company, visit www.MushroomsInc.com.

Mushrooms Inc. (MSRM), closed Tuesday's trading session at $0.027, off by 2.4566%, on 65,814 volume. The average volume for the last 3 months is 251,823 and the stock's 52-week low/high is $0.015/$0.15.

The QualityStocks Company Corner

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details for an eight-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 ("GLP-1") drugs and DehydraTECH-processed cannabidiol, alone and in combination. The contract for the study was awarded to a third-party, Health Canada-licensed research laboratory. Manufacturing of the compositions for the first eight of the 12 study arms has been completed, and those arms will commence as soon as possible at the testing laboratory, expected to begin within 45 days. Each arm of the study will be dosed for eight weeks following an acclimation period. During the study, over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for the purpose of analyzing detailed pharmacokinetic drug delivery. Body weight and blood glucose readings will be taken prior to the start of the study and at regular intervals during and at conclusion of the dosing period. Upon completion of the study, brain tissue will be analyzed to help determine whether DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms, as Lexaria has evidenced numerous times in previous animal studies.

To view the full press release, visit https://ibn.fm/iKl9i

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $3.38, up 12.6667%, on 1,003,638 volume. The average volume for the last 3 months is 2.294M and the stock's 52-week low/high is $0.6488/$3.6101.

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

This success has been attributed largely to the company's development and recent release of its Evolve soft bait product, a key addition to its growing product line

Year to date 2024, SenesTech reported 80% year-to-date revenue growth compared to the same period in 2023

Going forward, the company looks to introduce a soft bait contraceptive product for mice, having proven that its products work effectively on rats

SenesTech (NASDAQ: SNES), the rodent-fertility control experts and inventors of ContraPest(R), the only EPA-registered contraceptive for male and female rats, will be presenting at the Emerging Growth Conference, which is scheduled for March 6, 2024. According to the announcement, key company leaders will deliver a webcast presentation; the presentation will include time for a Q&A. The presentation is slated to begin at 1:10 p.m. ET. An archived replay of the presentation will be available on the Emerging Growth YouTube channel following the webcast. In addition, SenesTech representatives will be available for one-on-one investor meetings.

To view the presentation, visit https://ibn.fm/lQo2x

To view the full press release, visit https://ibn.fm/iJrER

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.

ContraPest®

SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Tuesday's trading session at $0.8799, up 1.9583%, on 41,126 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.6101/$.

Recent News

Zoned Properties Inc. (OTCQB: ZDPY)

The QualityStocks Daily Newsletter would like to spotlightFathom Zoned Properties Inc. (OTCQB: ZDPY).

Zoned Properties (OTCQB: ZDPY), a technology driven property investment company for emerging and highly regulated industries, including legalized cannabis, today announced that it has listed its cultivation property in Chino Valley, Arizona (the "Chino Valley Property") for sale at a purchase price of $16 million. The potential transaction marks a significant development in the company's strategic real estate portfolio optimization. "As part of our ongoing strategic review to enhance shareholder value, we are very pleased to announce our intention to sell our Chino Valley Property. The Chino Valley Property, which we now consider a non-core asset to our investment strategy, represents a significant capital reallocation opportunity for Zoned Properties. We expect that, if and when the Chino Valley Property is sold, the non-dilutive proceeds from the sale would be instrumental in supporting the company's future real estate portfolio acquisition plans," said Zoned Properties CEO Bryan McLaren.

"This is a pivotal step in our ongoing efforts to scale our direct-to-consumer real estate portfolio and unlock value for our shareholders. We believe that this strategic shift will position us to capitalize on the growing demand for retail dispensary properties in the cannabis real estate industry with strong cap rates creating long-term shareholder value. We will continue our ongoing strategic review with the sole intention of growing shareholder value and look forward to updating shareholders as appropriate."

To view the full press release, visit https://ibn.fm/HjJmA

Zoned Properties Inc. (OTCQB: ZDPY) is a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States. The company aspires to innovate within the real estate development sector, focusing on direct-to-consumer real estate that is leased to best-in-class cannabis retailers.

The company is redefining the approach to commercial real estate investment through its standardized investment process backed by its proprietary property technology. Zoned Properties has developed a national ecosystem of real estate services to support its real estate development process, including a commercial real estate brokerage and a real estate advisory practice.

With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is addressing the specific needs of a modern market in highly regulated industries. The company targets commercial properties that face unique zoning or development challenges, identifies solutions that can potentially have a major impact on their commercial value and then works to acquire the properties while securing long-term, absolute-net leases.

Zoned Properties targets commercial properties that can be acquired and rezoned for specific purposes, including the regulated and legalized cannabis industry. It does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law.

The company is headquartered in Scottsdale, Arizona.

Portfolio

The company’s investment properties are located in Arizona, Michigan and Illinois, with 100% occupancy and a weighted average lease term over 10 years. Each of the company’s leased properties is occupied by a commercial cannabis tenant. The company is expecting rental revenue from its property investment portfolio of greater than $2.5 million in calendar-year 2024.

Zoned Properties maintains a portfolio of properties that it owns, develops and leases. As of February 2024, the company leases land and/or building space at the six properties in its portfolio to licensed and regulated cannabis tenants in areas with established cannabis regulations and zoning procedures. Four of the leased properties are zoned and permitted as regulated cannabis retail dispensaries, and two of the leased properties are zoned and permitted as regulated cannabis cultivation and processing facilities.

The company considers the two cultivation sites in its portfolio as legacy properties and may consider selling or leveraging those properties to unlock equity and create capital availability in the future. The Zoned Properties investment thesis has evolved over the years as the cannabis industry has emerged, and the company is currently focused on investing capital into direct-to-consumer properties, located in state-markets with robust cannabis consumer demand in the industry.

Zoned Properties is in pursuit of property acquisitions that can be characterized as consumer-facing, retail dispensary properties that are positioned to be leased to retail dispensary cannabis tenants under net leasing structures. As of September 2023, the company has agreements in place to acquire new investment properties with new cannabis tenants located in Arizona, Missouri and Illinois. The company plans to initiate and target its investment process in Ohio and Maryland.

With a strategic shift in focus to direct-to-consumer real estate that is leased to best-in-class cannabis retailers in the industry, the company will continue to utilize its competitive edge when identifying excellent investment properties. Zoned Properties has a full pipeline of acquisition prospects and continues to utilize an extremely disciplined capital allocation approach.

Market Opportunity

According to MJBizDaily, a publication that has covered the North American cannabis business since 2011, combined U.S. medical and recreational cannabis sales were estimated at approximately $33.6 billion at the end of 2023, largely driven by the opening of new adult-use markets.

The publication projects that combined U.S. retail cannabis sales will reach upwards of $53.5 billion by 2027, according to an analysis published in its volume of cannabis market research, the MJBiz Factbook.

As of February 2024, 38 U.S. states had legalized medical, recreational or other limited use of cannabis. The Pew Research Center reports that, in January 2023, there were more than 11,000 licensed cannabis dispensaries in the U.S. In addition, global research firm IBISWorld reports that more than 40,000 U.S. localities have adopted regulations governing cannabis usage, production, processing and/or dispensing.

Management Team

Bryan McLaren is the Chairman and CEO of Zoned Properties. Previously, he worked as a Sustainability Consultant for Waste Management Inc., where he led the strategic development and operational implementation of zero-waste programs for clients. He was also appointed as a city Sustainability Commissioner. He holds a bachelor’s degree in business administration from the University of San Diego, a master’s degree in sustainable development from Northern Arizona University, an executive master’s degree in business leadership from Arizona State and an MBA with a specialty in sustainable development.

Berekk Blackwell is the President and COO of Zoned Properties. He previously spent time in developing domestic and international markets for Kahala Brands, a conglomerate of over 15 QSR franchises, including Cold Stone Creamery and Blimpie Subs. He later worked on developing QSR concepts for Revamp Corp. in Tokyo. After returning to the U.S., he served as president of Daily Jam, a limited-service breakfast and brunch chain. He holds a bachelor’s degree in business administration in finance from Fort Lewis College.

Patrick Moroney is the Director of Real Estate Acquisitions for Zoned Properties. Previously, he was one of the most successful Associate Brokers at Kidder-Mathews, focusing primarily on the regulated cannabis industry. He also worked as a commercial real estate broker rep at Cushman & Wakefield and Colliers International. He graduated from Arizona State University, after which he spent four years as a local sports broadcaster in Georgia and Iowa.

Kyle Gere is the Director of Advisory Services at Zoned Properties. He has years of licensing experience across multiple U.S. states in the medical and recreational cannabis markets. Since 2015, he has been involved in cannabis real estate transactions in Arizona and Michigan, managing a portfolio of medical marijuana properties. He attended Northern Arizona University, graduating with a bachelor’s degree in business administration in both management and marketing.

Zoned Properties Inc. (OTCQB: ZDPY), closed Tuesday's trading session at $0.51, up 4.0179%, on 19,490 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.35/$0.80.

Recent News

Sigyn Therapeutics Inc. (OTCQB: SIGY)

The QualityStocks Daily Newsletter would like to spotlightFathom Sigyn Therapeutics Inc. (OTCQB: SIGY).

Sigyn Therapeutics is developing four medical device candidates – Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) – designed to overcome current therapeutic limitations in healthcare

Sigyn Therapy(TM), the company's lead product candidate, is a single-use disposable device to treat life-threatening inflammatory conditions that are beyond the reach of drugs

ChemoPrep(TM) is designed to optimize the tumor-site delivery of chemotherapy, while ChemoPure(TM) intends to reduce the toxicity of chemotherapy by sweeping off-target chemotherapy out of the bloodstream

ImmunePrep(TM) is designed to reduce the presence of circulating drug decoys that interfere with the delivery of immunotherapeutic antibodies to treat cancer

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, will be participating at tomorrow's Emerging Growth Conference. The company announced that CEO Jim Joyce will give a live presentation; the presentation is slated to begin at 12 p.m. ET. According to the announcement, Joyce will provide an update on Sigyn Therapy(TM), the company's novel blood-purification technology designed to address life-threatening conditions that are beyond the reach of drugs, and will review the company's candidate products designed to enhance the benefit of chemotherapy and immunotherapeutic antibodies to treat cancer. The presentation will also include time for a Q&A. An archived copy of the webcast will be available following the presentation on the Emerging Growth YouTube channel.

To view the presentation, visit https://ibn.fm/9NH0s

To view the full press release, visit https://ibn.fm/cx10X

Sigyn Therapeutics Inc. (OTCQB: SIGY) is a development-stage medical technology company headquartered in San Diego, California. The company’s therapeutic candidates include Sigyn Therapy™ to address pathogen-associated inflammatory disorders, the ImmunePrep™ platform to enhance the performance of immunotherapeutic antibodies, ChemoPrep™ to improve the delivery of cancer chemotherapy and ChemoPure™ to reduce the toxicity of chemotherapy.

Sigyn created each of these technologies with two prerequisites in mind: 1) they must offer to overcome a clearly defined limitation in healthcare, and 2) their successful clinical advancement would offer a potential competitive advantage to established therapeutic organizations.

Sigyn Therapy™

The company is advancing Sigyn Therapy™ to treat pathogen-associated inflammatory disorders that are not addressed with FDA approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia and sepsis, which is the leading cause of hospital deaths in the United States.

The technology has the following attributes and capabilities.

  • Sigyn Therapy™ incorporates a formulation of adsorbent components that have more than 200,000 square meters (~50 acres) of surface area on which to adsorb and remove therapeutic targets from the bloodstream.
  • In vitro studies have demonstrated the ability of Sigyn Therapy™ to eliminate life-threatening pathogen and inflammatory disease targets from human blood plasma. In these studies, 12 relevant targets, including viral pathogens, bacterial toxins and inflammatory cytokines, were validated. Subsequent animal studies were completed at the University of Michigan.
  • Sigyn Therapy™ is highly efficient, as the entire circulatory system of a patient can pass through the device ~15-times during a four-hour treatment.
  • To allow for broad deployment, Sigyn Therapy™ is designed for use on the established infrastructure of dialysis and continuous renal replacement machines already located in hospitals and clinics around the world.

First-in-human studies of Sigyn Therapy™ plan to enroll dialysis dependent end-stage renal disease (ESRD) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population. There are more than 550,000 individuals with ESRD in the United States, which result in approximately 85 million dialysis treatments being administered each year.

The ImmunePrep™ Platform

Immunotherapeutic antibodies to treat cancer are among the most valued assets in global medicine. However, these drugs suffer from a severe limitation: they are poorly delivered to cancer cell targets, and, as a result, a majority of patients do not respond to therapy.

The Sigyn team recognized that just a small fraction of an antibody dose reaches its cancer cell target, yet a significant portion of the same dose can be sequestered by circulating decoys that display the target (antigen) binding site of the antibody. In response, Sigyn designed the ImmunePrep™ platform to leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that sweep antibody decoys from the bloodstream prior to the subsequent infusion (normal delivery) of the same therapeutic antibody.

The company believes its reverse decoy mechanism will increase the availability of antibodies to interact with their intended disease targets, and, simultaneously, the devices will also extract disease targets from the bloodstream to further improve patient benefit.

The opportunity to enhance the performance of therapeutic antibodies is significant. Consider that Pfizer’s $43 billion acquisition of Seagen Inc. and Amgen’s $27.8 billion acquisition of Horizon Therapeutics were the highest valued M&A deals of 2023. In both cases, transaction values were driven by market-cleared antibody assets.

Perhaps more revealing were the values placed on clinical-stage (pre-revenue) therapeutic antibody candidates. In this regard, consider Merck’s $10.8 billion acquisition of Prometheus Biosciences and Roche’s $7 billion acquisition of a clinical-stage antibody from Roivant Sciences.

In the backdrop of these M&A transactions, the immune checkpoint antibody Keytruda (Merck) became the world’s best-selling (non-vaccine) drug in 2023, with anticipated revenues of ~$24 billion.

ChemoPrep™ and ChemoPure™

Recent scientific publications have reported that only 1% of chemotherapy is delivered to the tumor cell targets of cancer patients. In response, the Sigyn team designed ChemoPrep™ to overcome a delivery limitation of the most commonly administered drug to treat cancer.

The company is developing ChemoPrep™ to reduce the circulating presence of tumor-derived exosomes (tumor exosomes), which interfere with chemotherapy delivery. High concentrations of tumor exosomes in the bloodstream correspond with poor treatment outcomes, whereas low concentrations of tumor exosomes correspond with more favorable outcomes. As compared to non-cancer subjects, exosome populations are reported to be 10x to 500x higher in the bloodstream of cancer patients. Based on these factors, the company believes there is a compelling scientific rationale to reduce the circulating presence of tumor exosomes prior to chemotherapy administration.

Inversely, the Sigyn team recognized that if 99% of chemotherapy was missing its target, then there was a need to eliminate off-target chemotherapy from the bloodstream to reduce toxicity and limit organ damage. This factor led to the design of ChemoPure™ to reduce treatment toxicity by reducing the presence of off-target chemotherapy from the bloodstream. The company believes that a reduction in chemotoxicity may also alleviate treatment-related fatigue and potentially temper the long-term health consequences associated with chemotherapy administration.

Management Team

James A. Joyce is Co-Founder, Chairman and CEO of Sigyn Therapeutics. He has more than two decades of public company CEO and corporate board leadership experience and is an inventor or co-inventor of 20 pending or issued patents, including those underlying ImmunePrep, ChemoPrep, ChemoPure and Sigyn Therapy. Previously, he was founder and CEO of Aethlon Medical, a therapeutic technology company that he built from a start-up to a Nasdaq-traded company. Under his leadership, Aethlon developed the first medical device to receive two breakthrough device designations from the FDA. Mr. Joyce graduated from the University of Maryland.

Annette Marleau, Ph.D., is Chief Scientific Officer at Sigyn Therapeutics. Prior to joining the company, she was Chief Technology Officer at Immunicom Inc. and Director of Research at Aethlon Medical Inc. Additionally, she is an inventor on pending and issued patents underlying blood purification therapies targeting cancer, inflammatory disorders and life-threatening infectious diseases. She holds a Ph.D. from Western University, an M.S. from the University of Guelph and a B.S. from the University of Waterloo in Canada.

Jerry DeCiccio, CPA, is CFO at Sigyn Therapeutics. He has more than 40 years of financial industry experience. Previously, he was CFO/COO at Intech Electromechanical, CFO/COO at GTC Telecom, CFO at Incomnet Communications and President at Cerebain Biotech Corp. He also served in senior financial roles at Parker Hannifin Corp., Waste Management Inc. and Newport Corp. He earned a bachelor’s degree in accounting and business administration from Loma Linda University and an MBA in finance and systems technology from the University of Southern California.

Sigyn Therapeutics Inc. (OTCQB: SIGY), closed Tuesday's trading session at $5, even for the day, on 305 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.08/$19.20.

Recent News

Astrotech Corp. (NASDAQ: ASTC)

The QualityStocks Daily Newsletter would like to spotlight Astrotech Corp. (NASDAQ: ASTC).

Legislators in Kansas have doubled back on a measure that would have legalized hemp in animal feed. Under federal law, hemp was legalized through the passage of the 2018 Farm Bill. The plant was subsequently removed from the list of controlled substances. Hemp is defined as the Cannabis sativa L. plant, and any part of it, including extracts, seeds, acids, isomers, cannabinoids and salts, among others, with not more than 0.3% of THC. Despite legalizing overall use of hemp, the Farm Bill did not allow the use of hemp or hemp products in food for animals or humans. Stephens also noted that despite not seeing any progress on this matter in 2023, this move forward felt like the Kansas Department of Agriculture was telling the industry it wanted things to work out. Overall, interest in industrial hemp products has increased greatly in the last five years following the plant's descheduling. It is expected that the size of the industrial hemp market will grow significantly over the next few years, reaching $18.1 billion by 2027. This growth is likely to bring more business opportunities for enterprises such as Astrotech Corp. (NASDAQ: ASTC) that specialize in making testing equipment for the hemp and marijuana industries.

Astrotech Corp. (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name.

In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (ATi) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.

Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (ECAC) certification for the TRACER 1000™, the world’s first mass-spec Explosives Trace Detector (ETD) used in airports worldwide. Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.

Astrotech is headquartered in Austin, Texas.

Subsidiaries

Astrotech Technologies Inc.

Astrotech Technologies Inc. (ATi) owns and licenses the platform mass spectrometry technology originally developed by 1st Detect. This technology is designed to be less expensive, smaller and easier to use than traditional mass spectrometers.

Unlike other technologies, ATi works under high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The company’s intellectual property includes 18 granted patents, along with extensive trade secrets.

ATi exclusively licenses the Astrotech Mass Spectrometer Technology to the three wholly owned subsidiaries of Astrotech.

1st Detect Corp.

1st Detect Corp. developed the TRACER 1000, the world’s first mass spectrometry-based explosives and narcotics trace detector. 1st Detect ETDs were developed for use at airports, cargo facilities and other secured locations and borders worldwide.

1st Detect’s commercial sales of the TRACER 1000 ETD, consumables and recurring maintenance services brought in $750,000 in total revenue during the fiscal year ended June 30, 2023. The Astrotech subsidiary recently secured two orders for a total of 24 Tracer 1000 units from two Romanian security and telecommunications companies, to be delivered during calendar 2023.

AgLAB Inc.

AgLAB Inc. is developing a series of mass spectrometers for use in the hemp and cannabis market, with an initial focus on optimizing yields in the distillation processes.

AgLAB, which uses the company’s proprietary AgLAB 1000-D2™ mass spectrometer, has been proven to improve distillation oil yields and bottom-line profits for hemp and cannabis producers. During field trials, AgLAB was able to improve ending-weight yields by an average of 24%.

BreathTech Corp.

BreathTech is developing the BreathTest-1000™, a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have a compromised condition including but not limited to a bacterial or viral infection. The company believes that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

Market Opportunity

A report by Mordor Intelligence, a research and advisory firm, put the global mass spectrometry market at $6.37 billion in 2023. The market is forecast to grow to $8.63 billion by 2028, achieving a CAGR of 6.25% during the forecast period.

One of the major driving factors for the growth of the mass spectrometry market is technological advancements in mass spectrometer devices, the report states. Key market players are continuously working toward advancing their existing products and launching innovative and advanced mass spectrometer devices.

Another major factor that is expected to boost market growth is increasing research and development expenditure by both government and private entities, according to the report. Mass spectrometry devices are also being used in the detection and analysis of COVID-19 and other disease samples, which may have a positive impact on the market.

Management Team

The Astrotech leadership team includes management executives, as well as industry and technology experts. The company continues to actively expand its talent pool to meet evolving demands.

Thomas B. Pickens III is Chairman, CEO and Chief Technology Officer of Astrotech Corp. He also serves as CEO of Astrotech subsidiaries ATi, 1st Detect, AgLAB Inc. and BreathTech Corp. Previously, he was the founder and president of Beta Computer Systems Inc. and T.B. Pickens & Co. He was founder and general partner of Grace Pickens Acquisition Partners L.P and managing partner of Sumpter Partners. He also served as CEO of Catalyst Energy Corporation and United Thermal Corporation and as president of Golden Bear Corp., United Hydro Inc. and Slate Creek Corp. He received a B.A. in Economics, Computer Science and Engineering from Southern Methodist University.

Jaime Hinojosa, CPA, is CFO at Astrotech Corp. He joined the company in 2015 and has served as its Corporate Controller since 2019. His previous roles with the company include Director of Finance, from 2017 to 2019, and Assistant Controller, from 2015 to 2017. Prior to joining Astrotech, Mr. Hinojosa worked as an Accounting Manager for O’Reilly Auto Parts and gained public accounting experience as an Audit Manager at Burton McCumber & Cortez LLP.

Astrotech Corp. (NASDAQ: ASTC), closed Tuesday's trading session at $7.62, off by 5.8096%, on 1,204 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $7.00/$15.11.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, announced that its subsidiary, Bollinger Motors, is expanding its footprint. The company has named an additional two dealership groups as it rolls out its commercial truck line. The two dealership groups — Nacarato Truck Centers and Nuss Truck and Equipment — span seven states and include 11 locations. A U.S.-based company headquartered in Michigan, Bollinger Motors develops all-electric commercial chassis cab trucks. The company is beginning its rollout with its B4 Chassis Cab, an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input, which is scheduled for release during the second half of 2024. "We are building our national dealer network very strategically to ensure that they share Bollinger's commitment to quality and customer service," said Bollinger Motors founder and CEO Robert Bollinger in the press release. "These two dealership groups represent some of the busiest trucking hubs in the country, and we welcome these new locations to the Bollinger family as we work to electrify fleets across the country."

To view the full press release, visit https://ibn.fm/JWqJF

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $6.56, off by 4.6512%, on 657,959 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.36/$5370.75.

Recent News

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

MasterCard has partnered with blockchain platform Polygon to create the MasterCard Artist Accelerator, a groundbreaking musician accelerator program that will leverage Polygon's technology to help emerging musicians use Web3 to grow their careers. The payment network processor will also include a MasterCard Music Pass in the program to provide emerging artists beyond the group selected for the accelerator with unique opportunities and educational resources via NFTs. MasterCard's entry into the blockchain space is poised to launch in spring and will connect industry mentors, including producers, musicians and DJs, with five aspiring artists from across the globe. The artists will receive guidance on how to build brands in the Web3 music space. They will also gain exclusive access to perks such as music and special releases as well as a first-of-its-kind guide on how to establish themselves in virtual worlds and build engaged communities. Polygon Studios CEO Ryan Wyatt said Web3 and blockchain can lead to the birth of a new type of musician who can grow a fanbase, earn a living and connect with their communities using new means of self-expression, all on their own terms. Polygon has also partnered with LGN.io and Warner Music Group to launch an NFT music listening, collecting and trading platform called LGND Music. Web3 is finding uses in many industries, as the MasterCard and Ploygon program shows its application in the music industry while NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) and other companies are applying it in healthcare e-commerce.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $1.35, off by 0.735294%, on 8,322 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.2101/$4.26.

Recent News

SOBRsafe Inc. (NASDAQ: SOBR)

The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

SOBRSafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol detection solutions, is collaborating with an existing behavioral health customer to expand the use of its proprietary SOBRsafe(TM) technology. SOBRSafe announced that the customer, which is not named for patient privacy reasons, has adopted the SOBRsure wearable band for continuous monitoring in an outpatient scenario; the customer had previously installed SOBRcheck in one of its facilities for point-of-care screening. "This customer is consistent with our approach to the behavioral health market — sign providers with multiple uses for our technology, prove its efficacy and expand within the account," said SOBRsafe chair and CEO Dave Gandini in the press release. "We are pleased to announce this dual adoption of both SOBRcheck and SOBRsure, and to again demonstrate our technology's strong utility across the full continuum of care."

To view the full press release, visit https://ibn.fm/ERA0G

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.

Products

The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.

SOBRsafe™

With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.

SOBRcheck™

SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.

SOBRsure™

SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.

 

Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Tuesday's trading session at $0.5999, off by 3.2419%, on 19,525 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2004/$2.53.

Recent News

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0)

The QualityStocks Daily Newsletter would like to spotlight Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0).

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0), a cybersecurity and internet privacy provider of Swiss-hosted solutions, offers a suite of secure cloud-based storage, disaster recovery, document management, encrypted email, and secure communication tools that do not rely on third-party cloud services. Sekur's products include SekurMail(R) with SekurSend/SekurReply, SekurVPN (R), and SekurMessenger(R). "Sekur offers customers peace of mind – with all customer information remaining confidential and safely stored in Switzerland using military-grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations," a recent article reads. "Sekur's entire suite of encrypted email, secure messaging and internet privacy solutions were designed to be user-friendly while providing customers with unparalleled security solutions – stopping attacks before they happen."

To view the full article, visit https://ibn.fm/xInXB

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure and private communications. The company distributes a suite of encrypted e-mails, secure messengers and secure communication tools. Sekur Private Data Ltd. sells its products through its own website at www.Sekur.com, approved distributors, and telecommunications companies. Sekur Private Data Ltd. serves consumers, businesses and governments worldwide.

Customer information is completely confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

The company owns 100% of its own infrastructure and, unlike its competitors, does not rely on third party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google cloud infrastructure.

Sekur Private Data has chosen Switzerland to locate its data storage because of the country’s neutrality, independence, strong privacy laws, long standing political stability and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the strongest and most competitive economies in the world.

The company is headquartered in Toronto, Ontario.

Products

Sekur Private Data distributes a privacy communications suite offering encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application. All solutions cater to consumers, SMBs, enterprises and governments.

  • SekurMail® is an encrypted email service offering a private, safe and powerful tool to communicate with everyone, either within the Sekur ecosystem or outside. SekurMail protects personal information and communications from being accessed by unauthorized parties. Its encryption and other security measures prevent messages from being intercepted, modified or tampered with, either in transit or while stored. SekurMail empowers the client to access information and communicate with anyone in the world, regardless of geographical or political barriers.
  • SekurVPN® creates a secure, encrypted connection between the client’s device and the Internet, giving clients access to the web safely and privately by routing their connections through a server and hiding their online actions. All the data sent and received is hidden from prying eyes. This includes the clients’ Internet Service Providers, as well as potential hackers and even government surveillance agencies. It can also help clients bypass geographical restrictions and censorship.
  • SekurMessenger® is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording and file transfer via any mobile device, tablet or desktop computer. Communications are transmitted only within secure servers. It’s designed for organizations that need to protect their flow of information and secure their communications with customers and partners. SekurMessenger is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged. It works for both licensed users of the app and intended message recipients who do not have the app.

Market Opportunity

An analysis from ReportLinker forecasts that the global cybersecurity market will grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors that are driving cybersecurity market growth, according to the report.

The global data privacy software market was estimated to be worth $1.68 billion in 2021 and is expected to grow from $2.36 billion in 2022 to $25.85 billion by 2029, achieving an eye-popping 40.8% CAGR during the forecast period, according to a Fortune Business Insights report titled ‘Data Privacy Software Market 2022-2029’.

The widespread shift toward remote working culture, evolving government data privacy regulations and the rapidly increasing adoption of Internet-of-Things devices are among the major factors propelling market growth, per the report.

Management Team

Alain Ghiai is founder, CEO and Director at Sekur Private Data. He also founded GlobeX Data S.A. (GDSA) in 2007 and has served as Director and CEO since then. He founded GlobeX Data Inc. (GlobeX US) in August 2012 and has served as Director and CEO since that time. He attended the California College of Arts in San Francisco, where he earned a Bachelor of Architecture. He has over 15 years of experience in the software industry and was instrumental in taking Sekur Private Data public in July 2019.

Scott Davis, CPA, CGA, is CFO at Sekur Private Data. He is also a partner at Cross Davis & Company LLP Chartered Professional Accountants. His experience includes CFO positions at several companies listed on the TSX Venture Exchange. He spent four years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davison & Company Chartered Professional Accountants as Auditor, five years with Pacific Opportunity Capital as Accounting Manager and two years at Jacobson Soda and Hosak, Chartered Professional Accountants. He obtained his CPA, CGA in 2003.

Learn more about the company’s management team by visiting its corporate page.

Sekur Private Data Ltd. (OTCQB: SWISF), closed Tuesday's trading session at $0.0469, off by 1.4706%, on 2,100 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0394/$0.1576.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a global infrastructure and holding company in the cannabis industry, is paying close attention to growing data showing the power of cannabis. "One recent study, conducted by postdoctoral research fellow Thomas Arkell, a PhD at Swinburne University of Technology in Melbourne, Australia, suggests that medical cannabis treatment may be associated with improvements in health-related quality of life among patients with a range of health conditions. The results of the study were published earlier this year by JAMA Network Open… This is just one of innumerable studies focused on cannabis… ‘Based on evidence currently available, the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value or that information on safety is lacking,'" reads a recent article, which contains excerpts from a report by NORML, a nonprofit organization that represents the interests of tens of millions of Americans who use marijuana responsibly. "This is positive news for MedCana, which has five companies focused on pharmaceutical cannabis production, as well as a software company focused on managing processes for plant-to-patient operations. In addition, the company recently rounded out its portfolio of holdings with the acquisition of an irrigation and greenhouse technology company… MedCana is building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world."

To view the full article, visit https://cnw.fm/f4lX8

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Tuesday's trading session at $0.031, off by 65.5556%, on 507 volume. The average volume for the last 3 months is 2,206 and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF)

The QualityStocks Daily Newsletter would like to spotlight Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) .

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) is a leading gold explorer in the Guiana Shield, South America. In early 2021, the Company announced an exciting new greenfield gold discovery at its Oko West project in Guyana, where, after 22 months of resource definition drilling, the Company has announced an initial Mineral Resource Estimate (MRE) containing 2.475 Moz of gold in Indicated resources at 1.84 g/t and 1.762 Moz of gold in inferred resources at 2.02 g/t contained within a pit shell outline. Preliminary metallurgy results performed by the company, consisting of 8 bottle roll tests obtained strong results, averaging just under 90% recoveries on average. The Company is continuing with additional development activities at Oko West, including environmental base line studies and additional metallurgical work relating to the delivery of a PEA by year end 2023. In addition, Reunion Gold is currently exploring several priority targets in the Oko West project area on which the company feels there is good potential to add additional resource ounces. This includes the opportunity to grow the initial mineral resource estimate (MRE) released on June 13, 2023, and to discover additional gold ounces at Oko West outside of the resource area.

The Guiana Shield remains one of the most prospective exploration locations globally for the discovery of world class orogenic gold deposits. The shield, including both Guyana and Surinam, contain large relatively underexplored greenstone belts, from which Reunion Gold expects many more significant gold discoveries could emerge in the coming years.

Oko West Project

Reunion Gold’s Oko West Project is a brand-new gold discovery in northwest Guyana located within the historical Oko gold district. Alluvial gold has been mined from the Oko district since the turn of the century, but very little primary gold has been mined or even explored for to the best of the company’s knowledge. The project comprises a prospecting license with an area of approximately 44 square kilometers and is 100% held by Reunion’s Guyanese subsidiary.

In 2020, Reunion Gold’s geochemical survey, trenching and initial 1000 m drill program discovered and confirmed the presence of gold mineralization in this Orogenic gold system. The gold occurs in the eastern edge of the project area, along a 6km long sheared contact between a granitoid intrusion and a meta volcanic-meta sedimentary rock package. The MRE is located within the Kairuni zone, which represents the northern most 1.9 km of the 6 km long contact.

“We are advancing our Oko West project along two tracks. The first is to advance the exploration programs outside of the Kairuni zone, aimed at outlining and discovering additional gold mineralization within our Prospecting License. On this front, I am very excited by the results from the initial Scout RC Geochem drill program that is defining new targets west of our Kairuni zone,” Rick Howes, President and CEO of Reunion Gold, stated in a recent news release. In addition to the targets west of the Kairuni zone, the company has also commenced exploration work on the southern ~ 4 km of the same sheared contact that hosts the Kairuni zone MRE. In addition, the company feels that the MRE marks the size of the Kairuni resource at a point in time and that there is good potential to continue to grow the resource. The MRE remains open at depth below the resource pit outline in the block 4 area and also to depth and along strike in the block 5 and 6 areas. In addition to the exploration programs, the second strategic track is to rapidly advance the Kairuni zone along the path to development. To that end the company is moving forward with the engineering and other studies, including more detailed metallurgical studies, that will support the release a PEA on the Kairuni zone by year end 2023 The company feels that the rapid advancement of development of Kairuni zone MRE, while in parallel continuing to explore for additional ounces on the project, is the best path to try and maximize shareholder value in the shortest period of time.

Guyana

Guyana boasts a long history of mining gold, bauxite, diamonds and manganese. Still, the greenstone belts of the Guiana Shield remain relatively unexplored when compared to the analogous regions of the West African Shield (Birimian), which, according to geological evidence, was once connected to the Guiana Shield, forming a contiguous craton prior to the Mesozoic period.

Despite a historical lack of accessibility and low exploration intensity, several significant large-scale projects have emerged in the Guiana Shield, including Aurora, Oko West, Oko Main, Toroparu and Omai. Guyana is English speaking with a British based parliamentary and legal system and boasts the world’s fastest growing economy on the back of significant offshore oil discoveries by Exxon and its partners. It is expected that a significant amount of the revenues from oil production will be invested in improving the infrastructure, education and health care and agriculture within the country.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, called 2022 the “strongest year for gold demand in over a decade.” Annual gold demand jumped 18% YoY due to “colossal central bank purchases, aided by vigorous retail investor buying and slower ETF outflows.”

Despite this spike in demand, total annual gold supply increased by just 2% in 2022, halting two years of successive declines but failing to challenge 2018 highs. This supply-demand imbalance could provide a favorable market environment as Reunion Gold continues to advance drilling programs at its 100%-owned Oko West Project.

Management Team

Successful exploration and the discovery of significant deposits in any given region require immense amounts of local knowledge and experience. This is the principle around which Reunion Gold has built its management team. In total, the company’s leadership boasts over 225 years of combined experience in the Guiana Shield.

David Fennell is the Executive Chairman of Reunion Gold, a position he has held since the company’s inception in 2003. He has 40 years of experience in the mining industry. He received a law degree from the University of Alberta in 1979 and practiced law until he founded Golden Star Resources Ltd. in 1983. During his term as President and CEO, Golden Star became one of the largest and most successful exploration companies. While at Golden Star, he was instrumental in the discovery and development of the Omai Gold Mine in Guyana and the Gross Rosebel Mine in Suriname. In 1998, Mr. Fennell became Chairman and CEO of Hope Bay Gold Corporation. He held this position through the merger of Hope Bay and Miramar Mining Corporation and remained as Executive Vice-Chairman and Director for the combined entity until its takeover by Newmont Mining Corporation in 2008. Mr. Fennell is currently a member of the board of directors of G Mining Ventures Corp. and Sabina Gold & Silver Corp.

Rick Howes, P.Eng., is the company’s President and CEO. He is a seasoned mining executive with over 39 years of experience in the mining industry, most recently as CEO of Dundee Precious Metals. Mr. Howes has extensive operating, technical and project development experience in both underground and open pit mines throughout Canada and internationally. In 2009, Mr. Howes joined Dundee Precious Metals, where, as VP and General Manager, he led the transformation of the Chelopech Mine in Bulgaria to reach world-class levels of performance. He became COO in 2011 and oversaw several significant growth capital development projects, including the expansion of the Chelopech Mine, the upgrade and expansion of the Tsumeb Smelter in Namibia and the development of the greenfield Ada Tepe open pit gold mine in Bulgaria. He was appointed CEO in April 2013, leading Dundee’s transformation from a junior gold producer to a multi-asset mid-tier gold producer generating strong free cashflow and solid returns to shareholders. Mr. Howes has been recognized as a visionary leader in mining, organizational innovation and transformation and was recognized as the Outstanding Innovator of 2016 by the International Mining Technology Hall of Fame.

Alain Krushnisky is the CFO of Reunion Gold. He brings to the company years of experience in the mining sector, including 10 years with Cambior Inc. (now IAMGOLD) in capacities such as Vice-President and Controller. Since 2004, Mr. Krushnisky has been doing consulting work for various publicly listed exploration and mining companies. He graduated from the University of Ottawa in 1983 with a bachelor’s degree in commerce and is a Chartered Professional Accountant.

Justin van der Toorn is the company’s VP Exploration. He is an exploration geologist with 18 years’ experience in the minerals industry, leading and managing exploration teams from grassroots activities through to discovery and resource definition drilling. Mr. van der Toorn’s previous experience has been in a range of commodity and deposit styles, including extensive work in Carlin-style gold, low- and high-sulphidation epithermal, porphyry and orogenic gold systems. He holds an MSci degree in Geological Sciences from the Royal School of Mines, Imperial College London. He is registered as a Chartered Geologist (CGeol) of the Geological Society, and a European Geologist (EurGeol) by the European Federation of Geologists.

Doug Flegg is the company’s business Development advisor. Doug has over 35 years’ experience in mining and mining finance with senior positions in research, portfolio management and global equity sales. Previously, Mr. Flegg was Managing Director Global Mining Sales with BMO Capital Markets where he was involved in raising $35 billion in over 200 corporate financings. Since 2016 he has been providing business development, strategic, and financing advice to corporate mining clients. Mr. Flegg also has a B.Sc. in Geology, work experience as a geologist and an MBA from Queens University.

Reunion Gold Corp. (OTCQX: RGDFF), closed Tuesday's trading session at $0.3186, up 8.4703%, on 375,060 volume. The average volume for the last 3 months is 121,700 and the stock's 52-week low/high is $0.24/$0.46.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Tuesday's trading session at $0.666, off by 1.9723%, on 71,159 volume. The average volume for the last 3 months is 231,658 and the stock's 52-week low/high is $0.372/$48.45.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.